title: Efficacy of zinc supplementation on serum calprotectin, inflammatory cytokines and outcome in neonatal sepsis - a randomized controlled trial.
abstract: OBJECTIVE
  To find out the efficacy of zinc supplementation in decreasing the levels of serum calprotectin and inflammatory cytokines with improvement in outcome in neonatal sepsis.
  
  
  METHODS
  Neonates with clinical signs suggestive of sepsis and at least two screening tests positive were randomized into two groups - zinc group and control group. The zinc group received 3 mg/kg of zinc sulfate monohydrate twice a day orally for 10 days along with antibiotics. The control group received antibiotics and supportive care. Serum zinc, calprotectin, TNF-α and IL-6 were estimated in serum at recruitment and 10 days later after completion of antibiotics. The babies were monitored daily till discharge and mortality rate was compared between the groups.
  
  
  RESULTS
  Baseline characteristics were similar between the groups. Serum zinc levels were considerably increased in the zinc group after supplementation. There was significant decline in concentrations of serum calprotectin, TNF-α and IL-6 (p < 0.05) in the zinc group. In the control group also, serum calprotectin and IL-6 levels were found to be decreased significantly after antibiotic treatment (p < 0.05), while TNF-α showed insignificant reduction. Kaplan-Meier analysis was performed to assess the survival time between the groups. The mortality was lower in the zinc group compared to the control group 5 versus 11, p= 0.12.
  
  
  CONCLUSIONS
  Neonates with sepsis who received zinc in addition to antibiotics showed significant reduction in serum calprotectin and inflammatory cytokines. Although mortality was lower in zinc group, it was not statistically significant.
authors.affiliation: a Department of Neonatology.
authors.forename: Newton
authors.initials: N
authors.lastname: Banupriya
authors.affiliation: a Department of Neonatology.
authors.forename: Ballambattu
authors.initials: B
authors.lastname: Vishnu Bhat
authors.affiliation: a Department of Neonatology.
authors.forename: Bosco Dhas
authors.initials: BD
authors.lastname: Benet
authors.affiliation: b Department of Biochemistry , and.
authors.forename: Magadi Gopalakrishna
authors.initials: MG
authors.lastname: Sridhar
authors.affiliation: c Department of Microbiology , Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) , Pondicherry , India.
authors.forename: Subash Chandra
authors.initials: SC
authors.lastname: Parija
mesh_terms: D000284:Administration, Oral; D000900:Anti-Bacterial Agents; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D015850:Interleukin-6; D053208:Kaplan-Meier Estimate; D039841:Leukocyte L1 Antigen Complex / Q000097:blood*; D008297:Male; D000071074:Neonatal Sepsis / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D014409:Tumor Necrosis Factor-alpha / Q000097:blood*; D015032:Zinc / Q000097:blood; D019287:Zinc Sulfate / Q000008:administration & dosage*
chemical_list: D000900:Anti-Bacterial Agents; D015415:Biomarkers; D015850:Interleukin-6; D039841:Leukocyte L1 Antigen Complex; D014409:Tumor Necrosis Factor-alpha; D019287:Zinc Sulfate; D015032:Zinc
keywords: ELISA; Newborns; biomarkers; mortality; zinc